Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia.

II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Research Resources (NCRR)
• Collaborator: Yale University

Criteria

• Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following:

• First-degree relative with HHT

• History of recurrent epistaxis or gastrointestinal bleeding

• Three or more skin telangiectasia

• Migraine headache meeting International Headache Society criteria 3 or more times a month for more than 1 year

• No pattern of daily headaches

• No severe head trauma

• No onset of headaches after 50 years of age

• At least 1 month since migraine prophylaxis

• At least 1 month since any of the following medications: Beta blockers; Calcium channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin re-uptake inhibitors

• Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed

• Creatinine no greater than 2.5 g/dL

• No allergy to soy

• No pregnant women

• No women with intent to become pregnant